Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Afamelanotide (CUV1647) implants in polymorphic light eruption
2006-005321-40Phase 3Completed
- Sponsor
- Clinuvel Pharmaceuticals
- Start
- Dec 2006
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in polymorphic light eruption (PMLE) comparing Afamelanotide implant with Placebo implant (2 arms). Primary endpoints: Physician's global severity assessment at Day 150 and Patient's global severity assessment at Day 150. Started Dec 2006; status: completed.
02
Drugs
Afamelanotide
03
Conditions
polymorphic light eruption (PMLE)
Beyond the preview
Go deeper on 2006-005321-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-005321-40.